PURPOSE: Review the results obtained from a Tobacco cessation Consulting Room in 2008.
METHODS: Retrospective descriptive analysis of the results obtained from patients who were treated at a Tobacco cessation Consulting Room from January 1st to December 31 in 2008; and the subsequent follow-up to complete one year.
RESULTS: 268 of 410 patients (56.3%) were male, mean age: 46 years and mean cigarettes/day: 27.1. Statistical significance between number of cigarettes smoked and sex, higher in males. Respiratory comorbidity: COPD 15.7%, asthma 9%, OSAHS 10.8% and HOT 1.9%. Cardiac comorbidity 7.83%, and psychiatric, 32.46%. Without treatment 44,4%, NRT 22.8%, bupropion 6.3% and varenicline 26.5%. Overall the 268 patients, successful treatment in 45 (16.8%), 29 men and 16 women; this percentage rises up to 29.6% if we do not consider those who did not attend the second consultation. Success among respiratory patients was longer compared to cardiac, with statistically significant results (27.1% vs. 4.7%, p <0.03) and also among non-psychiatric compared to psychiatric (19.8% vs. 10.3%, p <0.05). Among the patients who were treated pharmacologically, was found a greater success, statistically significant, among those who used varenicline compared to NRT or bupropion (35.2% vs. 21.5%, p <0.001).
CONCLUSIONS: 1. 62.92% did not start treatment (34.64% and 28.28%, first and second appointment respectively). 2. Cigarette consumption by males was significantly higher than women (28.51 vs. 25.08, p <0.02). 3. Overall treatment success 16.8%, amounting to 29.6% excluding those who do not attend the second consultation. 4. Greater success among respiratory than cardiac patients (27.1% vs. 4.7%) and among non-psychiatric than psychiatric ones (19.8% vs. 10.3%). 5. Greater success among varenicline than NRT or bupropion-treated (35.2% vs. 21.5%).
CLINICAL IMPLICATIONS: Smoking cessation treatment is effective but it requires patients commitment. There is an overall use of medication success of 16.8%, rising up to 29.6% if we exclude those who did not attend the second consultation. In our sample patients treated with Varenicline showed a success rate higher than the ones treated with bupropion or nicotine replacement therapy.
DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas González, Mariela Plenc Ziegler, Javier Cruz Ruiz, Sergio García Castillo, Raúl Godoy Mayoral, Miguel Ángel Moscardó Orenes, Juan Carlos Ceballos Romero, Patricia López Miguel, Jesús Jiménez López, Manuel Martínez Riaza
No Product/Research Disclosure Information